ImmuCell (NASDAQ:ICCC) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

ImmuCell (NASDAQ:ICCC) released its quarterly earnings data on Thursday. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.15, FiscalAI reports. The firm had revenue of $7.19 million for the quarter, compared to analysts’ expectations of $5.40 million. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%.

ImmuCell Price Performance

ICCC traded down $0.08 during trading hours on Thursday, hitting $10.90. The company’s stock had a trading volume of 44,696 shares, compared to its average volume of 24,272. The stock has a market cap of $98.64 million, a price-to-earnings ratio of -181.64 and a beta of 0.54. The business’s 50-day moving average price is $10.48 and its 200-day moving average price is $8.47. The company has a current ratio of 4.82, a quick ratio of 2.60 and a debt-to-equity ratio of 0.24. ImmuCell has a 12 month low of $4.52 and a 12 month high of $12.10.

Analyst Ratings Changes

ICCC has been the topic of a number of research reports. Wall Street Zen upgraded shares of ImmuCell to a “strong-buy” rating in a report on Saturday, June 27th. Weiss Ratings restated a “sell (d-)” rating on shares of ImmuCell in a research report on Thursday, July 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Insider Buying and Selling

In other ImmuCell news, CEO Boekhorst Paul Francis Oliv Te acquired 8,000 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was acquired at an average cost of $9.49 per share, with a total value of $75,920.00. Following the purchase, the chief executive officer directly owned 17,785 shares of the company’s stock, valued at approximately $168,779.65. This represents a 81.76% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC grew its position in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,852 shares of the biotechnology company’s stock after acquiring an additional 2,907 shares during the quarter. Geode Capital Management LLC owned about 0.79% of ImmuCell worth $500,000 at the end of the most recent reporting period. 13.47% of the stock is currently owned by institutional investors and hedge funds.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.